BLRX Nasdaq Pharmaceutical Preparations Financials FY2016βFY2025
BioLineRx Ltd. had $1.2M of revenue in fiscal 2025, down 95.9% on the year before.
Hi! I read BioLineRx Ltd.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
β95.9%
No. Sales fell 95.9% last year.
Does it make a profit?
β171.7%
No. It lost money last year.
Does profit turn into cash?
β686.4%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 8
Weak. It passes 3 of 8 health tests.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days BioLineRx Ltd. did it, and the next one. Share prices often move a lot on those days.
Next results
November 23, 2026
Monday Β· in 29 days
No past results dates on file yet.
KIRA Β· BioLineRx Ltd. had $1.2M of revenue in fiscal 2025, down 95.9% on the year before. Its operating margin was β871.8%, down 801.3Β pts: of every 100 in sales, about β872 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
KIRA Β· BioLineRx Ltd. lost $2.0M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$8.1M in fiscal 2025, β686.4% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably BioLineRx Ltd. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $13.0M | $10.6M | $4.3M | $10.4M | $3.3M |
| Interest coverage | β25.2x | β16.3x | β23.2x | β2.2x | β8.2x |
| Current ratio | 5.9x | 4.9x | 1.1x | 1.8x | 2.0x |
| Quick ratio | 5.9x | 4.9x | 1.1x | 1.6x | 1.8x |
| Total assets | $81.4M | $76.4M | $63.9M | $38.9M | $40.9M |
| Total liabilities | $13.3M | $25.5M | $50.7M | $25.4M | $17.6M |
| Shareholders' equity | $68.1M | $50.8M | $13.2M | $13.5M | $18.2M |
| Net debt (β = net cash) | β | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
KIRA Β· BioLineRx Ltd. passes 3 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 3 / 7 | 0 / 7 | 1 / 7 | 2 / 7 | β / 6 | 1 / 7 | 2 / 7 | 4 / 8 | 3 / 8 |
| Accruals ratio | β3.4% | β7.6% | 2.1% | β5.1% | β13.5% | β5.4% | 1.6% | β54.2% | 67.4% | 15.2% |
| Altman Z'' | β2.65 | β1.89 | β10.11 | β14.89 | β19.81 | β5.05 | β11.01 | β24.42 | β34.50 | β30.71 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | β | β | β | β | β | $0.0M | $0.0M | $4.8M | $28.9M | $1.2M |
| Gross profit | β | β | β | β | β | $0.0M | $0.0M | $1.1M | $19.7M | $1.0M |
| Research and development | $11.2M | $19.5M | $19.8M | $23.4M | $18.2M | $19.5M | $17.6M | $12.5M | $9.1M | $8.1M |
| Operating income | β$16.5M | β$25.2M | β$25.6M | β$28.1M | β$22.9M | β$24.8M | β$29.2M | β$49.7M | β$20.4M | β$10.3M |
| Interest expense | $0.0M | $0.0M | $0.5M | $2.3M | $1.5M | $1.0M | $1.8M | $2.1M | $9.1M | $1.3M |
| Income tax | β | β | β | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Net income | β$15.8M | β$24.4M | β$23.0M | β$25.4M | β$30.0M | β$27.1M | β$25.0M | β$60.6M | β$9.2M | β$2.0M |
| Diluted EPS | β$0.28 | β$0.27 | β$0.21 | β$0.17 | β$0.12 | β$0.04 | β$0.03 | β$0.06 | β$0.01 | $0.00 |
| Diluted shares | 0.06B | 0.09B | 0.11B | 0.15B | 0.25B | 0.66B | 0.77B | 0.96B | 1.20B | 2.47B |
| Cash flow | ||||||||||
| Cash from operations | β$14.5M | β$20.5M | β$24.2M | β$22.7M | β$23.2M | β$23.6M | β$26.2M | β$22.6M | β$43.9M | β$8.1M |
| Capital expenditure | $0.1M | $0.3M | $0.2M | $0.1M | $0.0M | $0.1M | $0.1M | $0.1M | $0.1M | $0.0M |
| Free cash flow | β$14.6M | β$20.9M | β$24.4M | β$22.7M | β$23.2M | β$23.7M | β$26.4M | β$22.7M | β$43.9M | β$8.1M |
| Depreciation and amortization | $0.5M | $0.5M | $0.4M | $0.9M | $0.9M | $0.7M | $0.6M | $0.6M | $0.4M | $0.5M |
| Stock-based compensation | $1.1M | $1.5M | $2.5M | $1.8M | $1.3M | $1.5M | $2.2M | $2.3M | $1.1M | $0.4M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $2.5M | $5.1M | $3.4M | $5.3M | $16.8M | $13.0M | $10.6M | $4.3M | $10.4M | $3.3M |
| Total debt | $0.3M | $0.3M | $8.7M | $8.5M | $5.8M | β | β | β | β | β |
| Current assets | $36.1M | $50.4M | $32.0M | $28.2M | $22.9M | $57.4M | $52.0M | $47.2M | $27.1M | $23.7M |
| Current liabilities | $3.7M | $6.7M | $6.8M | $12.0M | $10.6M | $9.7M | $10.7M | $42.8M | $15.4M | $12.1M |
| Inventory | β | β | β | β | β | β | $0.0M | $2.0M | $3.1M | $2.1M |
| Property and equipment, net | $2.6M | $2.5M | $2.2M | $1.8M | $1.3M | $1.0M | $0.7M | $0.5M | $0.4M | $0.2M |
| Intangible assets | $0.2M | $7.0M | $22.0M | $21.9M | $21.7M | $21.7M | $21.9M | $14.9M | $10.4M | $16.4M |
| Total assets | $38.9M | $61.0M | $56.2M | $53.6M | $47.3M | $81.4M | $76.4M | $63.9M | $38.9M | $40.9M |
| Total liabilities | $3.9M | $8.1M | $14.9M | $20.2M | $25.3M | $13.3M | $25.5M | $50.7M | $25.4M | $17.6M |
| Shareholders' equity | $35.0M | $52.9M | $41.3M | $33.4M | $22.0M | $68.1M | $50.8M | $13.2M | $13.5M | $18.2M |
| Margins | ||||||||||
| Gross margin | β | β | β | β | β | β | β | 23.1% | 68.0% | 80.5% |
| Operating margin | β | β | β | β | β | β | β | β1,035.3% | β70.5% | β871.8% |
| EBITDA margin | β | β | β | β | β | β | β | β1,023.1% | β69.0% | β829.8% |
| Net margin | β | β | β | β | β | β | β | β1,262.8% | β31.9% | β171.7% |
| FCF margin | β | β | β | β | β | β | β | β473.4% | β151.8% | β686.4% |
| Returns | ||||||||||
| Return on capital | β39.7% | β41.5% | β43.4% | β60.7% | β164.2% | β | β | β | β | β |
| Return on capital employed | β46.8% | β46.5% | β51.7% | β67.6% | β62.6% | β34.6% | β44.4% | β235.1% | β86.8% | β35.7% |
| Return on equity | β45.2% | β55.4% | β48.8% | β68.1% | β108.4% | β60.0% | β42.0% | β189.2% | β69.1% | β12.8% |
| Return on assets | β40.7% | β48.8% | β39.2% | β46.3% | β59.5% | β42.0% | β31.6% | β86.4% | β17.9% | β5.1% |
| Return on tangible equity | β45.5% | β53.1% | β118.7% | β221.5% | β9,500.3% | β58.3% | β86.2% | β | β306.1% | β110.8% |
| Growth | ||||||||||
| Revenue growth | β | β | β | β | β | β | β | β | 502.9% | β95.9% |
| Share count change | β | 60.2% | 20.7% | 34.8% | 72.7% | 162.2% | 16.7% | 24.5% | 24.4% | 105.8% |
| Financial health | ||||||||||
| Debt / equity | 0.0x | 0.0x | 0.2x | 0.3x | 0.3x | β | β | β | β | β |
| Interest coverage | β750.6x | β1,201.9x | β54.1x | β12.3x | β15.6x | β25.2x | β16.3x | β23.2x | β2.2x | β8.2x |
| Current ratio | 9.9x | 7.5x | 4.7x | 2.4x | 2.2x | 5.9x | 4.9x | 1.1x | 1.8x | 2.0x |
| Quick ratio | 9.9x | 7.5x | 4.7x | 2.4x | 2.2x | 5.9x | 4.9x | 1.1x | 1.6x | 1.8x |
| Capital allocation | ||||||||||
| Capex / revenue | β | β | β | β | β | β | β | 2.4% | 0.2% | 2.1% |
| Stock comp / revenue | β | β | β | β | β | β | β | 48.4% | 3.9% | 33.6% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 3.0 | 0.0 | 1.0 | 2.0 | β | 1.0 | 2.0 | 4.0 | 3.0 |
| Altman Z'' | β2.7 | β1.9 | β10.1 | β14.9 | β19.8 | β5.0 | β11.0 | β24.4 | β34.5 | β30.7 |
| Accruals ratio | β3.4% | β7.6% | 2.1% | β5.1% | β13.5% | β5.4% | 1.6% | β54.2% | 67.4% | 15.2% |
Source: SEC EDGAR XBRL filings (CIK 0001498403). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. The ADS ratio could not be read from the filing, so market cap and valuation are not shown. For information only β not investment advice. Check the original filings before relying on any figure.
